The herpes simplex virus single-stranded DNA-binding protein, ICP8, localizes initially to structures in the nucleus called prereplicative sites. As replication proceeds, these sites mature into large globular structures called replication compartments. The details of what signals or proteins are involved in the redistribution of viral and cellular proteins within the nucleus between prereplicative sites and replication compartments are poorly understood; however, we showed previously that the dominant-negative d105 ICP8 does not localize to prereplicative sites and prevents the localization of other viral proteins to prereplicative sites (J. Virol. 74 (2000) 10122). Within the residues deleted in d105 (1083 to 1168), we identified a region between amino acid residues 1080 and 1135 that was predicted by computer models to contain two ␣-helices, one with considerable amphipathic nature. We used site-specific and random mutagenesis techniques to identify residues or structures within this region that are required for proper ICP8 localization within the nucleus. Proline substitutions in the predicted helix generated ICP8 molecules that did not localize to prereplicative sites and acted as dominant-negative inhibitors. Other substitutions that altered the charged residues in the predicted ␣-helix to alanine or leucine residues had little or no effect on ICP8 intranuclear localization. The predicted ␣-helix was dispensable for the interaction of ICP8 with the U L 9 origin-binding protein. We propose that this C-terminal ␣-helix is required for localization of ICP8 to prereplicative sites by binding viral or cellular factors that target or retain ICP8 at specific intranuclear sites.
Introduction
The HSV-1 single-stranded DNA-binding protein, ICP8, is a 128-kDa multifunctional zinc metalloprotein (Gao et al., 1988; Gupte et al., 1991) encoded by the U L 29 gene (McGeoch et al., 1988) . ICP8 preferentially binds singlestranded DNA over double-stranded DNA in a nonspecific, cooperative manner (Lee and Knipe, 1985) . ICP8 is a nuclear protein that, along with the six other HSV replication proteins, including the viral polymerase (U L 30) and its accessory factor (U L 42), the trimeric helicase-primase complex (U L 5/U L 8/U L 52), and the origin-binding protein (U L 9), is required for viral DNA synthesis (Challberg, 1986; Conley et al., 1981) . ICP8 can destabilize DNA helices (Boehmer and Lehman, 1993a) and may have a role in viral genome recombination and processing as shown by its ability to promote DNA strand transfer (Bortner et al., 1993) and renaturation of complementary DNA strands (Dutch and Lehman, 1993) . In addition to its role in viral DNA replication, ICP8 has been shown to regulate viral gene expression by stimulating late gene expression from progeny genomes (Gao and Knipe, 1991) and repressing transcription from the parental genome (Godowski and Knipe, 1983 , 1986 . ICP8 has been shown to interact either physically or functionally with several viral proteins, including associating with the HSV U L 9 origin-binding protein and stimulating its helicase activity (He and Lehman, 2001 ; Lee and Lehman, 1997; Makhov et al., 1996; Boehmer, 1998; Boehmer and Lehman, 1993b) , modulating the activity of the viral polymerase (U L 30) (Chiou et al., 1985; Hernandez and Lehman, 1990; O'Donnell et al., 1987; Ruyechan and Weir, 1984) , and promoting the helicase activity of the viral helicase-primase complex (U L 5/U L 8/ U L 52) (Falkenberg et al., 1998; Hamatake et al., 1997; Le Gac, et al., 1996) . In the absence of viral DNA replication, e.g., in the presence of the polymerase inhibitor PAA or in the initial stages of the viral life cycle, ICP8 targets to structures within the nucleus named prereplicative sites (de Bruyn Kops and Knipe, 1988; Quinlan et al., 1984) . These nuclear matrix-associated structures form adjacent to cellular structures referred to as ND10 sites (Ascoli and Maul, 1991; Ishov and Maul, 1996; Lukonis et al., 1997; Uprichard and Knipe, 1997) . It is believed that at least some of these prereplicative sites are precursors to large, globular structures called viral replication compartments, which form as viral DNA replication proceeds (de Bruyn Kops and Knipe, 1994; Maul et al., 1996; Uprichard and Knipe, 1997) . Various viral processes, such as viral DNA synthesis (de Bruyn Kops et al., 1998; Phelan et al., 1997) , late gene transcription (Knipe et al., 1987; Phelan et al., 1997; Randall and Dinwoodie, 1986; Rice et al., 1994) , and capsid assembly (de Bruyn Kops et al., 1998) , take place within replication compartments.
Several functional regions within ICP8 have been mapped, including a nuclear localization signal located in the C-terminal 28 amino acid residues (Gao and Knipe, 1992) , a DNA-binding region located within amino acid residues 564 -860 (Gao et al., 1988; Gao and Knipe, 1989; Ruyechan, 1988) , two regions involved in cooperative DNA binding, two cysteine residues, cys245 and cys455 (Dudas and Ruyechan, 1998) , the C-terminal 60 amino acid residues (Mapelli et al., 2000) , and a zinc-binding motif between amino acid residues 499 and 512 (Gao et al., 1988) .
While the regions associated with various activities discussed above have been mapped, little is known about the sequence(s) within ICP8 required for intranuclear targeting to prereplicative sites or replication compartments during infection. In this study, we describe the construction of ICP8 point mutants that are deficient for intranuclear targeting. The dominant-negative d105 ICP8 is missing amino acid residues 1083 to 1168 in the C-terminus of the protein.
When expressed in the context of wild-type viral infection, either via transfection or in the stably expressing cell line V2.6, d105 ICP8 reduces viral replication by 50-to 100-fold (Chen and Knipe, 1996; Gao and Knipe, 1991) . The reduced viral replication is due to a 5-fold reduction in viral DNA synthesis and a 50-to 100-fold block in late gene transcription (Chen and Knipe, 1996) . Overexpression of wild-type ICP8 can overcome this block, suggesting that d105 ICP8 acts in a competitive manner (Gao and Knipe, 1991) . While the d105 ICP8 can still bind single-stranded DNA (Gao and Knipe, 1991) , it does not localize to prereplicative sites or replication compartments (McNamee et al., 2000) ; instead, it is diffusely distributed throughout the nucleus. The mutant d105 protein may exert its dominant-negative activity in the cell line V2.6 at two stages: (1) preventing the localization of viral and cellular proteins to prereplicative sites in 80% of cells, and (2) inhibiting the maturation of replication compartments from prereplicative sites in the remaining 20% of cells (McNamee et al., 2000) . This suggested that the region deleted in d105 contained sequences required for intranuclear localization. To further map these sequences, we introduced mutations into an ICP8-GFP fusion protein gene.
Results
ICP8 localizes initially to prereplicative sites and then to replication compartments within the nucleus of infected cells (Quinlan et al., 1984) ; however, the dominant-negative d105 ICP8 is distributed diffusely in the nucleus and blocks the formation of prereplicative sites and replication compartments when present during HSV-1 infection (McNamee et al., 2000) . The d105 mutant ICP8 lacks residues 1083-1168, suggesting that a function required for intranuclear targeting may lie within this region. To further define what elements within this region were important for ICP8 intranuclear localization, we used the PHD secondary structure prediction program (Rost, 1996) to identify regions with possible ␣-helical or ␤-sheet structures. The region spanning amino acid residues 1080 to 1135 was predicted to be ␣-helical with a possible turn at residues 1112 to 1116 (Fig. 1A) . No reliable secondary structure prediction was apparent for the region spanning amino acid residues 1137 to 1196. When the predicted ␣-helix from amino acid residues 1118 to 1135 was plotted on a helical-wheel diagram, the amphipathic nature was apparent (Fig. 1B) . One side of the predicted helix was composed completely of hydrophobic residues, while the other face contained hydrophilic residues including several negatively charged residues and one positively charged residue.
Construction and localization of ICP8-GFP point mutants
To determine if this amphipathic ␣-helix was necessary for localization of ICP8 within the nucleus, we used a site-directed mutagenesis approach to introduce helix-destabilizing proline residues or charge-to-alanine mutations in the predicted ␣-helix. We also used a random PCR mutagenesis strategy to generate mutations within the C-terminal 80 amino acid residues of ICP8 to identify other residues or regions necessary for intranuclear targeting. Mutations generated by either method were made in a 270-bp SalI fragment that was sequenced and reinserted into a vector that expressed the ICP8 coding sequences as a fusion protein with GFP at its C-terminus. We then evaluated the ability of the mutant ICP8-GFP fusion proteins to localize within the nucleus. We transfected Vero cells with plasmids expressing the mutant ICP8-GFP fusion proteins, and at 24 h after transfection we infected the cells with the HD-2 ICP8 mutant virus in the presence or absence of the viral DNA synthesis inhibitor phosphonoacetic acid (PAA). We used the replication-defective HD-2 virus to ensure that the ICP8 mutant protein could localize within the nucleus in the absence of complementing wild-type ICP8. Similar results were observed when the cells were infected with the wildtype virus (data not shown). The infected cells were processed for GFP fluorescence at 5.5 h postinfection. When the ICP8-GFP fusion protein was expressed in Vero cells in the absence of infection, ICP8-GFP was distributed diffusely throughout the nucleus ( Fig. 2A) . Upon infection, the ICP8-GFP fusion protein localized to replication compartments (Fig. 2B) . If PAA was present during infection, the ICP8-GFP fusion protein localized to prereplicative sites in the nucleus (Fig. 2C) . The H1126A ICP8-GFP molecule retained the ability to localize to replication compartments (Fig. 2D ), but the A1128P ICP8-GFP molecule was distributed diffusely within the nucleus (Fig. 2E) . Several single or double charge-to-alanine substitutions, such as D1119A, E1123A, H1126A, E1127A, E1129A, D1119A/E1123A, or H1126A/E1127A, did not significantly alter the ability of the ICP8-GFP mutant fusion protein to target within the nucleus (Table 1 ) with a similar intranuclear localization as seen for the H1126A ICP8-GFP protein (Fig. 2D ) or wildtype ICP8-GFP (Fig. 2B ). Other ICP8 mutants with substitutions outside the predicted ␣-helix, such as L1135H/ F1167L, V1141E, G1149S/H1175R, and P1179Q, also had little effect on the ability of the ICP8-GFP to localize to replication compartments (Table 1) , but this small number of mutants by no means saturated this region of ICP8. The ICP8-GFP molecules with proline substitutions A1121P ICP8-GFP, L1122P ICP8-GFP, and A1128P ICP8-GFP (Fig. 2E ) exhibited a diffuse nuclear distribution (Table 1) , thus showing an altered ability of the mutant ICP8-GFP Fig. 1 . Secondary structure prediction of a region of ICP8. (A) Secondary structure prediction for ICP8 amino acid residues 1081 to 1196 by the PHD program. The ICP8 sequence is found in the "AA" line. The overall structure prediction is given in the "PHD sec" line with H, ␣-helix; E, ␤-strand; L, loop. The reliability of the structure prediction is given in the "Rel sec" line with a range of 0 -9 with 9 being the most reliable. (B) Helical-wheel diagram of amino acid residues 1118 to 1135. proteins to localize properly in the nucleus, presumably by disrupting the predicted ␣-helix in this region. However, we cannot rule out the possibility that the alanine or the leucine residues themselves were required for proper structure and function. The S1133G substitution would be predicted to disrupt an ␣-helix; however, this substitution was at the very end of the predicted ␣-helix and may not have a dramatic effect upon the structural integrity of the helix. The F1144C substitution was interesting in that it altered the total number of cysteines in ICP8. It was possible that the introduction of another cysteine in the C-terminus of ICP8 disrupted structure within this region or more generally within ICP8.
Construction and localization of ICP8 point mutants
Once ICP8-GFP mutants that were defective for intranuclear localization were identified, we constructed vectors expressing the mutant proteins without GFP fused to the C-terminus to ensure that the GFP moiety itself was not contributing to the observed localization defect. Fig. 3 shows a Western blot of lysates from transfected Vero cells expressing the ICP8 mutants. The mutant proteins appeared to migrate slower than the wild-type protein due to an extra 18 amino acid residues at the C-terminus that remained after removing the GFP coding sequences. These extra residues did not significantly alter the function of the ICP8 proteins because certain mutants, such as the single or double charge-to-alanine substitutions, could still localize to replication compartments (Fig. 4) or complement an ICP8 null virus (Table 2) .
We first determined if the mutant ICP8 molecules could localize properly within the nucleus in HD-2 infected Vero cells. In this experiment, we transfected Vero cells with equal amounts of the plasmid encoding the indicated mutant ICP8. At 24 h posttransfection, we infected the Vero cells with the HD-2 virus. At 5.5 h postinfection, the cells were processed for immunofluorescence to detect ICP8 using the 39S monoclonal antibody. The 39S antibody generally only recognizes wild-type ICP8 at prereplicative sites or in replication compartments (S.L. Uprichard and D.M. Knipe, manuscript submitted for publication). We have evidence 4D, E, and I), suggesting that the ␣-helix in the C-terminus of ICP8 is important for intranuclear localization. The small number of prereplicative sites observed may reflect the ability of ICP8 interacting proteins to partially complement the mutant's structural instability by binding and stabilizing local structure. The recognition of the mutant ICP8 molecules by 39S monoclonal antibody also suggested that the global protein structure of the d105, A1121P, A1128P, and F1144C ICP8 molecules was intact because they could form the 39S epitope. The triple mutant C1149R/N1153S/K1171N was not recognized by the 39S monoclonal antibody. When expressed without GFP fused to its C-terminus, the triple mutant did not localize to the nucleus; rather, the majority of it was observed in the cytoplasm when detected by immunofluorescence using the 3-83 polyclonal anti-ICP8 antibody (Fig. 4L ). The K1171N substitution in this mutant altered a lysine residue in the predicted nuclear localization signal (NLS) to an uncharged asparagine, thus possibly disrupting the NLS and subsequently altering the ability to localize to the nucleus. The GFP fusion version of this mutant localized to the nucleus, suggesting that the presence of GFP at the C-terminus of this mutant somehow suppressed the nuclear localization defect. This result confirmed that nuclear targeting is required for acquisition of the epitope recognized by the 39S monoclonal antibody.
HD-2 complementation assay
To determine if the ICP8 point mutants could complement the growth of an ICP8-deficient virus, we infected Vero cells expressing the indicated mutants with the HD-2 ICP8 mutant virus. Only the double mutant D1119A/ E1123A ICP8, which retained the ability to properly target within the nucleus, could complement the growth of the HD-2 virus to near wild-type levels observed with the transfection of the wild-type control plasmid pCMV-8.3 plasmid ( Table 2 ). The F1144C, A1121P, and A1128P ICP8 molecules all failed to complement HD-2, with the viral yield near the levels of those obtained when the control plasmid pCI or a plasmid expressing d105 ICP8 were used (Table 2) . Thus the ICP8 mutants that did not localize to replication compartments, such as the F1144C, A1121P, and A1128P ICP8 molecules, failed to complement the growth of an ICP8 deficient virus.
Construction and localization of a C-terminal region of ICP8 fused to GFP
The results described above suggested that the C-terminal portion of ICP8 containing the ␣-helix may comprise a targeting or retention signal required for localization to viral replication structures. If this were true, the C-terminal portion of ICP8 might be sufficient to target a heterologous protein to prereplicative sites or replication compartments during infection. We tested this by fusing amino acid residues 1007-1196 of ICP8 to the N-terminus of GFP, which generated a fusion protein that we named cterm8-GFP. In transfected Vero cells, the cterm8-GFP protein migrated with approximately the predicted mass of 48 kDa (data not shown). We ascertained if this region of ICP8 was sufficient for intranuclear localization to replication compartments by determining if it could efficiently localize to specific structures within the nucleus in the context of HSV infection. The cterm8-GFP fusion protein retained the ICP8 NLS (Gao and Knipe, 1992) , so it could still target into the nucleus. Vero cells transfected with plasmids that expressed either wild-type ICP8-GFP or cterm8-GFP were subsequently mock-infected (Figs. 5A and C, respectively) or infected with HSV (Figs. 5B and D, respectively) . At 6 h postinfection with wild-type virus, ICP8-GFP was clearly localized to viral replication compartments (Fig. 5B) . In contrast, the cterm8-GFP fusion protein was distributed diffusely in the nucleus after infection with HSV (Fig. 5D) , suggesting that the cterm8-GFP protein localized poorly, if at all, to replication compartments. Thus, the C-terminal 190 amino acid residues of ICP8 were not sufficient to specifically target to or retain GFP at replication compartments. 
The dominant-negative d105 ICP8 mutant binds U L 9
It was also possible that this portion of ICP8 interacted with other viral or cellular proteins that were required for intranuclear localization. It is known that ICP8 interacts with the C-terminus of the HSV U L 9 origin-binding protein (Boehmer and Lehman, 1993b) . Thus, it was conceivable that the predicted ␣-helix in ICP8 was required for interacting with U L 9. We tested this by determining the ability of wild-type or d105 ICP8 to bind a Staphylococcus aureus protein A-U L 9 fusion protein immobilized on IgG Sepharose (Arbuckle and Stow, 1993) . Both the wild-type and the d105 ICP8 proteins bound the wild-type B1 protein A-UL9 fusion protein (Fig. 6 ). The mutant D27 protein A-U L 9 fusion protein, which was previously shown not to bind ICP8 (Boehmer et al., 1994) , bound neither the wild-type nor the d105 ICP8 proteins (Fig. 6) . Thus, residues 1083 to 1168 of ICP8, including the predicted ␣-helix, were not required for interactions with the U L 9 origin-binding protein.
Altered U L 42 localization in the presence of the ICP8-GFP point mutants
In addition to not localizing to prereplicative sites itself, the dominant-negative d105 ICP8 protein inhibits the localization of other viral proteins to prereplicative sites (McNamee et al., 2000) . We tested the ability of the ICP8-GFP mutants to block the intranuclear localization of another viral protein to determine if the point mutants acted in a dominant-negative manner similar to d105 ICP8. We transfected plasmids encoding ICP8-GFP mutant proteins into Vero cells and at 24 h postinfection infected with wild-type KOS 1.1 virus. We then used indirect immunofluorescence at 5.5 h postinfection to visualize the intranuclear distribution of the U L 42 polymerase processivity factor in cells that expressed the mutant ICP8-GFP protein. The wild-type ICP8-GFP fusion protein and the double mutant H1126A/ E1127A ICP8-GFP did not alter the localization of U L 42 to replication compartments (Figs. 7A and B, respectively) , whereas in the cells expressing the L1122P ICP8-GFP, A1128P ICP8-GFP, and A1121P ICP8-GFP, U L 42 was dis- tributed diffusely within the nucleus (Figs. 7C, G , and I, respectively). Small structures containing F1144C ICP8-GFP and U L 42 were observed in some cells (Figs. 7E and F) , but the structures were not as large as those observed in wild-type ICP8-GFP expressing cells, indicating that this mutant may have a weak inhibitory activity. The presence of ICP8 from the wild-type genome may partially complement the localization defect observed with F1144C ICP8-GFP (Fig. 7F) . Small structures within the nucleus containing A1121P ICP8-GFP (Fig. 7J) were observed, but these structures did not colocalize with U L 42, so these structures may be aggregates of the mutant protein within the nucleus or may also be due to the presence of wild-type ICP8 expressed as a result of wild-type infection. We conclude that the three proline substitutions that disrupted the predicted ␣-helix all blocked the proper intranuclear localization of U L 42. This block may manifest itself at multiple stages during viral infection. The proline substitution mutants may block the initiation of viral replication, thus preventing replication compartment formation, or the proline mutants may bind a factor required specifically for the targeting of viral proteins to replication compartments, thus preventing the accumulation at specific intranuclear sites.
The ICP8 proline point mutants act in a dominantnegative manner
To determine if the mutants that blocked U L 42 intranuclear localization also blocked viral replication in a dominant-negative manner, we performed plaque-reduction assays. Wild-type viral DNA was cotransfected with plasmids expressing wild-type ICP8 (pCMV-8.3), a mutant ICP8 (pCMV-d105, pCMV-F1144C, pCMV-A1121P, pCMV-L1122P, or pCMV-A1128P), or the vector plasmid (pCI). If the expressed protein acted in a dominant-negative manner, the number of plaques would be reduced. The expression of wild-type or F1144C ICP8 did not significantly reduce the number of plaques compared to the vector pCI plasmid control (Table 3 ). In contrast, A1121P ICP8, L1122P ICP8, and A1128P ICP8 reduced the plaque number to the levels observed in the presence of the dominant-negative d105 ICP8 (Table 3) . These results suggested that A1121P ICP8, L1122P ICP8, and A1128P ICP8 acted in an dominantnegative manner similar to d105 ICP8, possibly by competitively binding and titrating out limited viral or cellular factors required for viral replication that would normally interact with wild-type ICP8.
Discussion
ICP8 localizes initially within the nucleus to nuclearmatrix-associated prereplicative sites (Quinlan et al., 1984) , which form adjacent to cellular ND10 sites Lukonis et al., 1997; Maul et al., 1996 ; Uprichard and Knipe, 1997) . Following the onset of viral DNA replication, ICP8 localizes to replication compartments (de Bruyn Kops and Quinlan et al., 1984) , which grow and coalesce to form larger replication compartment structures that eventually fill the nucleus (Taylor et al., 2003) . The mechanisms required for intranuclear localization and compartmentalization are poorly understood. To further the studies of intranuclear targeting and compartmentalization, we used the HSV-1 single-stranded DNAbinding protein, ICP8, as a model protein.
Requirements for ICP8 intranuclear localization
To identify residues within ICP8 required for intranuclear localization, we mutagenized a specific region of ICP8 in an ICP8-GFP fusion protein. In this report, we demonstrated the effect of introducing point mutations into a region in the C-terminus of ICP8 predicted to be an amphipathic ␣-helix. We isolated three types of mutations, which will be discussed in more detail below, consisting of (1) substitutions that did not alter the ability of ICP8 to localize within the nucleus, (2) a substitution, F1144C, that altered the ability of ICP8 to localize within the nucleus, but did not have a strong dominant-negative phenotype, and (3) substitutions that abolished the ability of ICP8 to localize within the nucleus and had a strong-dominant negative phenotype as shown by the ability to inhibit viral growth in a plaque reduction assay. ICP8 mutant molecules which had one or two charged residues substituted with alanines, such as D1119A, E1123A, H1126A, E1127A, E1129A, D1119A/ E1123A, and I11126A/E1127A, retained the ability to localize to structures within the nucleus. This suggests that individual charged residues within this region of ICP8 are not critical for intranuclear localization. Other substitutions outside the region predicted to contain an ␣-helix had little or no effect on the intranuclear localization of ICP8. These substitutions, such as L1135H/F1167L, V1141E, and P1179Q, were in a region that contained no definitive secondary structure as predicted by the PHD program. The exception to this was F1144C ICP8, which had an altered number of cysteine residues in the protein. Wild-type ICP8 contains 22 cysteines, and it has previously been shown that ICP8 has two electrophoretic conformational forms (Knipe et al., 1982) . It was suggested that these two forms of ICP8 coexist within an infected cell based on the evidence that (1) the relative abundance of one form or the other depended upon the time of harvest postinfection, (2) that the preparation of extracts was performed in the presence of reducing agents that would prevent spontaneous disulfide bond formation during the process, and (3) that the two forms were still observed when the extracts were reacted with the alkylating agent N-ethylmaleimide (NEM) (Knipe et al., 1982) . It is possible that the introduction of an additional cysteine in F1144C ICP8 may have deleterious effects on ICP8 function or structure by disrupting proper cysteine pairing. It has also been shown that cysteines may be involved in optimal ICP8 DNA binding as treatment of ICP8 with NEM inhibited DNA binding (Ruyechan, 1988) . In addition, the C-terminus of ICP8 has been shown to be required for cooperative DNA binding (Mapelli et al., 2000) ; thus, the introduction of another cysteine (or the removal of the phenylalanine residue) may interfere with optimal cooperative DNA binding. The introduction of the F1144C substitution did not result in a strong dominant-negative phenotype, suggesting that this mutant cannot act as a competitive inhibitor of wild-type ICP8 function. In contrast, substitutions that would disrupt the predicted ␣-helix with a proline, such as L1122P, A1128P, and A1121P, lost the ability to localize to prereplicative sites and replication compartments. We believe that the disruptions alter the structural integrity of an ␣-helix that is required to interact with other viral or cellular proteins that are needed for proper intranuclear targeting.
ICP8 interactions with infected cell components
When ICP8 is expressed in the absence of the other viral replication proteins, it is distributed diffusely within the nucleus and it is poorly recognized by the 39S conformation-specific, monoclonal anti-ICP8 antibody, which generally only recognizes ICP8 at prereplicative sites or in replication compartments (S.L. Uprichard and D.M. Knipe, manuscript submitted for publication). We hypothesize that ICP8 interacts with other viral or cellular factors, which induces a conformational change in ICP8, and that it is this conformational change that forms or exposes the epitope that reacts with the 39S monoclonal antibody. ICP8 is known to directly bind DNA (Lee and Knipe, 1985) and the origin-binding protein (Boehmer et al., 1994; Boehmer and Lehman, 1993b) , suggesting that one or both of these molecules may be involved. It is also known that the presence of the helicase-primase complex is sufficient to localize ICP8 to punctate prereplicative sites in transfected cells (Liptak et al., 1996) , so interaction(s) with one or more of components of the heterotrimeric helicase-primase complex may be required to drive a conformational change. Upon binding the other viral replication proteins, ICP8 can then interact with other viral or cellular factors required for targeting or anchoring ICP8 and its associated proteins to prereplicative sites. The exact identity of the viral or cellular factors involved remains unknown, but they may include viral DNA, other viral or cellular proteins, and components of the nuclear matrix. It may be possible to identify proteins that induce the ICP8 conformational change by generating mutations in d105 that relieve its dominant-negative phenotype. For example, if either U L 9 or DNA binding are required to drive the conformational change to generate a dominant-negative protein, than the disruption of these activities or interactions may produce a version of d105 that no longer has dominant-negative activity.
We propose that a region in the C-terminus of ICP8 that is predicted to contain an amphipathic ␣-helix spanning amino acid residues 1083 to 1135 is critical for intranuclear targeting or retention, possibly by interacting with viral or cellular factors that target or retain ICP8 and its associated proteins within the nucleus to prereplicative sites. Other regions of the ICP8 protein are likely to be required for intranuclear localization because the C-terminal 190 amino acid residues were not sufficient to relocalize GFP from a diffuse distribution within the nucleus to replication compartments. It is possible that the proline mutants and d105 ICP8 act in an inhibitory manner by binding one or more viral or cellular factors required for proper intranuclear localization, but cannot interact with others. Thus, these mutant ICP8 proteins may act to titrate out viral or cellular factors required for localization to prereplicative sites in the nucleus. The ICP8 proline substitutions still reacted with the 39S conformation-specific antibody, suggesting that the mutants were still capable of interacting with the proteins required to form or unmask the 39S epitope. We have also shown that the U L 9 origin-binding protein and the d105 ICP8 bind, so this interaction is not significantly altered by the deletion in this region. It would be informative to identify other viral or cellular factors that bind ICP8 to better define the interaction. Once identified, the role of these interactions in the targeting of proteins within the nucleus may be elucidated.
General mechanisms for intranuclear compartmentalization
The nucleus does not contain obvious physical barriers, such as the lipid membrane that separates the cytoplasm from the interior of the endoplasmic reticulum or the nuclear membrane with its nuclear pores that act as gates to separate the contents of the cytoplasm and the nucleus, that would facilitate nuclear compartmentalization. However, some mechanism(s) must exist to ensure proper intranuclear targeting and compartmentalization. Some attempts have been made to identify regions or signals in nuclear proteins or RNA that may constitute targeting/sorting/retention signals that direct or hold proteins or RNA within specific regions of the nucleus, such as the nucleolus (Lohrum et al., 2000) or the nuclear speckles (Eilbracht and Schmidt-Lach-mann; 2001). While some progress is being made in determining the minimal requirements for targeting to the abovenoted nuclear subcompartments, it is still unclear what mechanism is involved in targeting or anchoring proteins to the nuclear-matrix-associated ND10 sites. It is known that a small, ubiquitin-like molecule, called SUMO or PIC1, can be covalently attached to the ND10-associated protein PML, and that this modification is required for PML to associate with ND10 (Boddy et al., 1996; Muller et al., 1998; Sternsdorf et al., 1997) . Another ND10-associated protein, Sp100, is also "SUMOylated," but this is not required for ND10 association, suggesting that SUMO modification itself is not intrinsically an intranuclear targeting mechanism (Sternsdorf et al., 1997) . However, Sp100 and other ND10-associated proteins do require PML-SUMO for their association with ND10, suggesting that PML-SUMO may play a critical role in recruiting other cellular proteins to the site (Zhong et al., 2000) . To date, there is no evidence that ICP8 is modified by the addition of SUMO or that it interacts specifically with PML-SUMO.
There is little sequence or structural similarity between viral proteins that associate with ND10, such as the HSV ICP0 protein , the cytomegalovirus ie1 and ie2 proteins (Ahn et al., 1998; Ishov et al., 1997) , the Epstein-Barr virus EBNA-5 protein (Szekely et al., 1996) , the SV40 large T antigen (Carvalho et al., 1995; Ishov and Maul, 1996) , and the adenovirus E1A and E4orf3 proteins (Carvalho et al., 1995) , making it difficult to determine the minimum requirements for intranuclear localization or association with ND10. At least one study has reported that the adenovirus E1A protein requires the (D)LXCXE motif for its association with ND10 structures (Carvalho et al., 1995) . Although this motif is also implicated in pRb binding, it was found that other E1A mutants incapable of binding pRb, but retain the (D)LXCXE motif, still associate with ND10 in transfected cells, suggesting that pRb binding is not required for targeting or retention (Carvalho et al., 1995) . ICP8 contains the sequence LXLXE between amino acid residues 1089 and 1093, which is disrupted in d105 ICP8. It is possible that this sequence may be similar to the LXCXE motif and may work via a related mechanism. The exact requirements for the HSV-1 ICP0 intranuclear targeting are also poorly understood. Although the RING finger motif in the N-terminus of ICP0 is required for the disruption of ND10 , it is not required for association with ND10; however, a region in the C-terminus required for ND10 association has been identified Maul and Everett, 1994) . These differences described above as well as the lack of significant sequence similarities may suggest that multiple pathways or mechanisms are involved in the targeting or retention of viral proteins to specific sites within the nucleus. Efforts to crystallize ICP8 (Mapelli and Tucker, 1999) to determine its three-dimensional structure may be critical for the further understanding of how ICP8 may bind and target cellular or viral proteins to prereplicative sites and replication compartments. In the future, it may be possible to take advantage of these interactions as pharmacological targets to prevent intranuclear targeting of proteins to prereplicative sites and thus limit viral replication.
Materials and methods

Cells and viruses
African green monkey kidney (Vero) and human 293 cells were grown and maintained in Dulbecco's modified Eagle's medium (Mediatech, Inc.) with 5% fetal bovine serum (Gibco) ϩ 5% bovine calf serum (Hyclone), glutamine, streptomycin, and penicillin (DMEM ϩ 10% FCS). The ICP8-expressing cell lines S2 (Gao and Knipe, 1989) and V827 (Da Costa et al., 2000) were grown and maintained in DMEM ϩ 10% FCS plus G418 (400 g/ml).
The herpes simplex virus 1 KOS1.1 wild-type strain, originally obtained from M. Levine, was propagated and assayed on Vero cells. The HD-2 ICP8 mutant virus (Gao and Knipe, 1989) was propagated on either S2 or V827 cells, which contain the ICP8 gene or the ICP8 and ICP27 genes, respectively. All infections were conducted at an m.o.i. of 20.
Plasmids
The plasmids pCMV-8.3, pCMV-d105, and pCMV-ICP8GFP express wild-type ICP8, the mutant d105 ICP8, and ICP8-GFP, respectively, under the control of the CMV immediate early promoter. The plasmid pSVd101 expresses the d101 mutant ICP8, which lacks residues 17 to 563 (Gao and Knipe, 1989) . The plasmids pCMV-8.3 and pCMVd105 were generated by removing a 3.8-kbp EcoRI/AvrII fragment containing the entire ICP8 ORF from pSV8.3 (Gao and Knipe, 1991) or pSVd105 (Gao and Knipe, 1991) and cloning them into the EcoRI and XbaI sites of pCI, respectively. To construct pCMV-ICP8GFP, a 732-bp NotI fragment containing an enhanced green fluorescent protein (GFP) open-reading frame from pGreenLantern (Gibco-BRL) was cloned into the NotI site of pCI⌬AflII to generate pCI⌬A-GFP. A 3.8-kbp EcoRI/AvrII fragment containing the entire ICP8 ORF from pSV8.3 was cloned into the EcoRI and XbaI sites of pCI⌬A-GFP. The fusion protein ORF was generated by mutating the ICP8 stop codon via PCR-mediated site-directed mutagenesis with Pfu DNA polymerase (Stratagene) (one cycle 95°C 2 min; 12 cycles 95°C 30 s, 55°C 1 min, 68°C 18 min). The two primers used for changing the stop codon to an arginine residue were 5Ј-CAACCCCTCTCAGCATATCCAACG-3Ј (antisense) and 5Ј-CGTTGGATATGCTGAGAGGGGTTG-3Ј (sense) (Life Technologies). The altered nucleotide is underlined. After PCR amplification, the reaction was digested with DpnI, and 1 l of the reaction was used to transform bacteria. Candidate clones were sequenced to ensure that the appropriate sequence change was introduced. The site-directed point mutants were constructed by mutagenizing a 270 bp SalI fragment (containing ICP8 sequence coding for amino acids 1117 to 1196) removed from pCMV-ICP8GFP and cloned into the plasmid vector pCI⌬AflII. Altering the 270-bp sequence in the pCI background allowed us to fully sequence the clones and to minimize the introduction secondary mutations that might have arisen during the mutagenesis protocol. Once sequenced, the SalI fragment was recloned into the SalI site of either pCMV-8.3 or pCMV-ICP8GFP to express the indicated mutant ICP8 or ICP8-GFP proteins. The GeneEditor in vitro site-directed mutagenesis system (Promega) was used to construct the sitedirected point mutants. The primers used to construct the site-directed point mutants were L1122P, 5Ј-ACGCGGC-CCCGGAGGTGGCGCAC; E1127A, 5Ј-AGGTGGCG-CACGCGGCCGAGGCC; E1129A, 5Ј-ACGAGGCCGCG-GCCCTAGTCAGC; A1128P, 5Ј-TGGCGCACGCCGAG-GCCCTAG; H1126A/E1127A, 5Ј-GACTAGGGCCTCG-GCCGCGGCCGCCACCTCCAGGGCCGCGTC; E1119A, 5Ј-GACGCGGCCCTGGCGGTGGCGCACGAGGCCGA-GGCC, D1119A/E1123A, 5Ј-GGCGAGTGGTCGACGG-CCGCGGCCCTGGCGGTGGCGGCCGCGGCC. The single mutant E1123A was isolated as a clone resulting from a mutagenesis reaction that was intended to generate the double mutant D1119A/E1123A, but only the E1123A mutation was generated in that particular clone.
The random point mutations were introduced using an error-prone PCR protocol. The PCR (7 mM MgCl 2 , 0.5 mM MnCl 2 , 1 mM dCTP and dTTP, 0.2 mM dGTP and dATP, 0.3 M primers, 50 ng pCMV-cterm8-GFP template DNA in a total volume of 50 l) was run for 30 cycles (1 min at 94 C, 1 min at 45 C, 1 min at 72 C). The forward primer was 5Ј-CCTTATTTTTGACCGCACCCG and the reverse primer was 5Ј-CGCCGATGGAGTGTTCTGTTG. The 270-bp SalI fragment was isolated from the 1000-bp fragment generated by the PCR and cloned into the SalI site of pCMV-ICP8GFP to screen for mutations that altered ICP8-GFP localization. With this system, only mutants that retained the ICP8 reading frame would give rise to an ICP8-GFP fusion protein that could be detected by GFP fluorescence. We picked 64 colonies for analysis. Of those, 22 expressed an ICP8-GFP protein that was detectable by GFP fluorescence in transfected Vero cells. We sequenced the 22 isolates to determine if there were mutations in the ICP8 sequence. Of these 22 clones, 10 clones had one or more mutations that resulted in an altered amino acid sequence.
The pCMV-cterm8GFP plasmid was constructed by first generating a second NheI site in the plasmid pCMV-ICP8GFP using the GeneEditor site-direct mutagenesis kit (Promega). The primer used to generate the NheI site was 5Ј-GAACTGGGCTAGCCTGATGG. The resulting plasmid was digested with NheI to remove a 3.5-kb fragment. The vector was religated to generate the plasmid pCMVcterm8GFP. This plasmid expresses ICP8 amino acid residues 1007 to 1196 fused to the N-terminus of GFP. The nuclear localization signal was left intact in the ICP8 sequence.
Plasmids pB1 and pD27 expressing amino acid residues 535 to 851 or 535 to 824 of the origin-binding protein U L 9 fused to the C-terminus of Staphylococcus aureus protein A (Arbuckle and Stow, 1993; Boehmer and Lehman, 1993b) , respectively, were kindly provided by Nigel Stow (MRC Virology Unit, Institute of Virology, Glasgow).
Indirect immunofluorescence and GFP fluorescence
For indirect immunofluorescence and GFP fluorescence studies, Vero cells were plated on 12-mm coverslips in a 24-well plate. At the indicated times posttransfection or postinfection, the cells were washed briefly in PBS and then fixed for 5 min in 3.7% formaldehyde in PBS. After washing with PBS for 5 min, the cells were subsequently permeabilized with Ϫ20°C acetone for 2 min. The cells were then rinsed in distilled water and washed for 5 min in PBS. Primary antibody was then applied at a 1:50 dilution of one of the following for the 39S anti-ICP8 monoclonal antibody (Showalter et al., 1981) and the 5H11D6 anti-U L 42 monoclonal antibody (Gao et al., 1993) , or 1:200 dilution for the 3-83 anti-ICP8 polyclonal antibody (Knipe et al., 1987) . After washing three times for 5 min in PBS, a 1:100 dilution of a rhodamine-conjugated goat anti-mouse antibody was used as a secondary antibody for detection. After a final wash in PBS, the coverslips were mounted onto glass slides with gelatin. Cells were viewed with an Axioplan 2 (Zeiss) microscope equipped with an Orea cooled CCD camera (Hamamatsu Photonics). A Zeiss 63X plan Apochromat objective was used. Images were collected with the OpenLab software package (Improvision). Figures were prepared with Canvas 5.0 (Deneba).
Complementation of ICP8 mutant virus
Vero cells were transfected with the indicated plasmids expressing either wild-type or mutant ICP8 using Lipofectamine reagent (Gibco-BRL) following the manufacturer's recommendations. At 24 h posttransfection, the cells were infected with the HD-2 ICP8 mutant virus. The cells were washed twice (40 mM sodium citrate, 135 mM NaCl, 10 mM KCl, pH 3.0) for 30 s before being overlayed with new media. One day later, the cells were harvested by two rounds of freeze/thaw and sonication. The viral yield was determined by titration on the V827 complementing cell line.
Preparation of protein extracts
Protein extracts were obtained from two 150-cm 2 culture flasks of 293 cells transfected with pCMV8.3 and pCMVd105. At 48 h posttransfection, the cells were washed twice with phosphate-buffered saline, collected by centrifugation, and resuspended in 2 ml of high salt buffer (1.2 M NaCl, 20 mM HEPES-NaOH, pH 7.5, 10% (v/v) glycerol, 1 mM DTT, 1 mM EDTA, one Complete-Mini protease inhibitor cocktail tablet (Roche) per 7 ml buffer). The lysates were sonicated on ice three times for 30 s and then clarified by centrifugation at 4°C in an Eppendorf microfuge. The lysates were dialyzed overnight against low salt buffer (100 mM NaCl, 20 mM HEPES-NaOH, pH 7.5, 10% (v/v) glycerol, 1 mM DTT, 0.1 mM EDTA) and then cleared by centrifugation at 4°C for 30 min in an Eppendorf microfuge. After the addition of 1 M MgCl 2 to 20 mM and 200 units of DNase I, the lysates were incubated at 4°C for 2 h and then stored at Ϫ80°C.
U L 9-binding assay
Five hundred-milliliter cultures of DH5 E. coli containing either the pB1 or pD27 plasmid (Arbuckle and Stow, 1993; Boehmer and Lehman, 1993b) were grown in Luria broth overnight at 37°C. The pelleted cells were washed three times with 100 ml TE (10 mM Tris-HCl, pH 7.6, 1 mM EDTA). After resuspension in 10 ml lysis buffer (50 mM Tris-Cl, pH 7.6, 150 mM NaCl, 0.05% Tween 20, 1 mM EDTA, one Complete-Mini protease inhibitor cocktail tablet per 10 ml buffer), lysozyme was added to 200 g/ml, and the cells were incubated at room temperature for 20 min. The cells were sonicated on ice, and the lysates were clarified by centrifugation at 4°C in a Sorvall centrifuge at 15,000 rpm for 1 h. The lysates were incubated overnight at 4°C after the addition of 1 M MgCl 2 to 20 mM and 400 units of DNase I. The lysates were aliquoted and stored at Ϫ80°C.
One milliliter of B1 or D27 lysate was added to 0.5 ml of IgG Sepharose Fast Flow 6, equilibrated as per manufacturer's directions (Pharmacia Biotech), batchwise in microfuge tubes. The slurry was incubated at 4°C for 30 min with gentle agitation. The IgG Sepharose slurry was washed three times with TST buffer (50 mM Tris-Cl, pH 7.6, 150 mM NaCl, 0.05% Tween 20), and then twice with low salt buffer (100 mM NaCl, 20 mM HEPES-NaOH, pH 7.5, 10% (v/v) glycerol, 1 mM DTT, 0.1 mM EDTA). After 0.5 ml of either wild-type or d105 containing extract was added to the protein A-U L 9/IgG Sepharose preparations, the slurry was incubated for 1 h at 4°C with gentle agitation. The slurry was centrifuged at 4°C in an Eppendorf microfuge for 1 min. The supernatant was removed and kept as the unbound fraction. The slurry was subsequently washed twice with 0.5 ml of low salt buffer and then 0.5 ml of high salt elution buffer (1 M NaCl, 20 mM HEPES-NaOH, pH 7.5, 10% (v/v) glycerol, 1 mM DTT, 0.1 mM EDTA). The two 0.5-ml wash fractions were combined for a final volume of 1 ml. A portion of each fraction (1/10 total volume) was separated by SDS-PAGE, transferred to PVDF membrane (BioRad), and probed with the 3-83 ICP8 polyclonal antibody. On another gel, decreasing 2-fold dilutions equivalent to 1/10, 1/20, and 1/40 of the input protein extracts were analyzed in parallel to monitor input and recovery levels.
Western blot analysis of proteins
For the immunodetection of wild-type or mutant ICP8 by Western blot, the 3-83 polyclonal antibody was used at a dilution of 1:1000 in TBST (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Tween 20). The anti-GFP polyclonal antibody (Clontech) was used at a dilution of 1:1000 in TST. The membrane was blocked with TBST plus 5% milk for 30 min at room temperature before the addition of the 3-83 antibody. The membrane was washed three times for 15 min with TBST at room temperature after primary and secondary antibody incubations. An HRP-conjugated goat antirabbit secondary antibody (Santa Cruz Biotechnology) was used at a dilution of 1:5000 in TBST. Enhanced chemiluminescent reagents were used as directed by the manufacturer (Amersham Pharmacia Biotech).
Plaque reduction assay
Vero cells in 6-well trays were transfected using Lipofectamine. A total of 4 g of DNA consisting of 0.25 g KOS 1.1 viral DNA, 0.5 g of the indicated wild-type or mutant ICP8 plasmid, and 3.25 g of plasmid pCI DNA as carrier DNA was used per transfection reaction. At 24 h posttransfection, the cells were washed with PBS and overlayed with DMEM ϩ 1% FBS and human sera to allow plaques to form. The cells were fixed at 4 days posttransfection for plaque enumeration.
